Despite ongoing pricing concerns, Fresenius' dialysis operations should support stable results.
Negative currency effects and natural disasters in the U.S. weighed on Fresenius Medical Care’s third-quarter results of 3% revenue and 2% net income growth, but excluding these temporary issues, performance mostly tracked our expectations. Year-end performance should fall short of management’s unchanged year-end outlook, which excludes the negative effect of these items. We’re leaving our fair value estimate and narrow-moat rating unchanged. Fresenius’ results continue to show less exposure to ...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.